A
Atsena Therapeutics
Bringing the life-changing power of genetic medicine to reverse or prevent blindness
About Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company that operates in the healthcare sector, specifically in the field of genetic medicine. The company's primary focus is on developing treatments to reverse or prevent blindness. Their target market includes patients suffering from inherited retinal diseases, one of the most common causes of blindness in children.
Read full description
Atsena Therapeutics is currently conducting a Phase I/II clinical trial to evaluate a potential therapy for this condition. The company's business model revolves around the development and commercialization of these gene therapies. They generate revenue through the sales of these therapies once they have been approved for use in the market.
The company's pipeline of clinical and preclinical assets is powered by an adeno-associated virus (AAV) technology platform. This platform is designed to overcome the challenges presented by inherited retinal disease. In simple terms, AAV is a type of virus that can be used to deliver genes into cells. This technology is being used to develop a dual AAV vector-based gene therapy to prevent blindness from MYO7A-associated Usher syndrome (USH1B), a disease that affects both the retina and the inner ear.
Atsena Therapeutics' approach is patient-centric, with therapies being developed based on the specific needs of each patient's condition. The company is making rapid advancements in its field, showing promise in its ability to bring life-changing treatments to the market.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Durham, United States
- Employees
- 45
- Open positions
- 8
- Dealroom signal
- 89.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b, b2c
Latest news
Press, funding announcements and product moves mentioning Atsena Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2025 | $150M | $600M | Wellington Management · Abingworth · Lightstone Ventures · Osage University Partners | ↗ |
| EARLY VCOther financing | Aug 2023 | $24M | $275M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Atsena Therapeutics is 7.3K monthly website visits, down 61.6% over the last three months. Atsena Therapeutics's team grew 28.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Hatteras Venture Partners
Foundation Fighting Blindness
Sofinnova Investments
Abingworth
Lightstone Ventures
Osage University Partners
Retinal Degeneration Fund- MFManning Family Foundation
Series B and later2 investors entered at this stage
Other known investors1 additional known investor
University of Florida
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atsena Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atsena Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.